- Home
- WIW vs RGNX Comparison
WIW vs RGNX Comparison
Compare WIW & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- RGNX
- Stock Information
- Founded
- WIW 2004
- RGNX 2008
- Country
- WIW United States
- RGNX United States
- Employees
- WIW N/A
- RGNX N/A
- Industry
- WIW Finance Companies
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WIW Finance
- RGNX Health Care
- Exchange
- WIW Nasdaq
- RGNX Nasdaq
- Market Cap
- WIW 540.9M
- RGNX 445.5M
- IPO Year
- WIW N/A
- RGNX 2015
- Fundamental
- Price
- WIW $8.91
- RGNX $9.01
- Analyst Decision
- WIW
- RGNX Strong Buy
- Analyst Count
- WIW 0
- RGNX 8
- Target Price
- WIW N/A
- RGNX $28.50
- AVG Volume (30 Days)
- WIW 229.9K
- RGNX 712.8K
- Earning Date
- WIW 01-01-0001
- RGNX 08-07-2025
- Dividend Yield
- WIW 11.14%
- RGNX N/A
- EPS Growth
- WIW N/A
- RGNX N/A
- EPS
- WIW N/A
- RGNX N/A
- Revenue
- WIW N/A
- RGNX $155,782,000.00
- Revenue This Year
- WIW N/A
- RGNX $327.08
- Revenue Next Year
- WIW N/A
- RGNX N/A
- P/E Ratio
- WIW N/A
- RGNX N/A
- Revenue Growth
- WIW N/A
- RGNX 74.95
- 52 Week Low
- WIW $8.01
- RGNX $5.04
- 52 Week High
- WIW $9.37
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- WIW 63.57
- RGNX 56.43
- Support Level
- WIW $8.74
- RGNX $7.83
- Resistance Level
- WIW $8.87
- RGNX $9.25
- Average True Range (ATR)
- WIW 0.06
- RGNX 0.52
- MACD
- WIW 0.01
- RGNX 0.04
- Stochastic Oscillator
- WIW 98.82
- RGNX 87.37
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.